NO20005351D0 - Paroksetin 10-kamfersulfonat for behandling av CNS lidelser - Google Patents

Paroksetin 10-kamfersulfonat for behandling av CNS lidelser

Info

Publication number
NO20005351D0
NO20005351D0 NO20005351A NO20005351A NO20005351D0 NO 20005351 D0 NO20005351 D0 NO 20005351D0 NO 20005351 A NO20005351 A NO 20005351A NO 20005351 A NO20005351 A NO 20005351A NO 20005351 D0 NO20005351 D0 NO 20005351D0
Authority
NO
Norway
Prior art keywords
paroxetine
treatment
cns disorders
camphor sulfonate
camphor
Prior art date
Application number
NO20005351A
Other languages
English (en)
Other versions
NO20005351L (no
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20005351D0 publication Critical patent/NO20005351D0/no
Publication of NO20005351L publication Critical patent/NO20005351L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20005351A 1998-04-25 2000-10-24 Paroksetin 10-kamfersulfonat for behandling av CNS lidelser NO20005351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808894.1A GB9808894D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001246 WO1999055699A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20005351D0 true NO20005351D0 (no) 2000-10-24
NO20005351L NO20005351L (no) 2000-10-24

Family

ID=10831007

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005351A NO20005351L (no) 1998-04-25 2000-10-24 Paroksetin 10-kamfersulfonat for behandling av CNS lidelser

Country Status (18)

Country Link
EP (1) EP1076659A1 (no)
JP (1) JP2002513020A (no)
KR (1) KR20010042929A (no)
CN (1) CN1306530A (no)
AP (1) AP2000001958A0 (no)
AU (1) AU3618699A (no)
BG (1) BG104973A (no)
BR (1) BR9909878A (no)
CA (1) CA2329913A1 (no)
EA (1) EA200001105A1 (no)
GB (1) GB9808894D0 (no)
HU (1) HUP0102298A2 (no)
IL (1) IL139018A0 (no)
NO (1) NO20005351L (no)
PL (1) PL343596A1 (no)
SK (1) SK15902000A3 (no)
TR (1) TR200003083T2 (no)
WO (1) WO1999055699A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CN104402708A (zh) * 2014-12-07 2015-03-11 河南领先科技药业有限公司 一种樟脑酸钠的生产方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására

Also Published As

Publication number Publication date
WO1999055699A1 (en) 1999-11-04
BG104973A (bg) 2001-09-28
PL343596A1 (en) 2001-08-27
CN1306530A (zh) 2001-08-01
BR9909878A (pt) 2000-12-26
TR200003083T2 (tr) 2001-02-21
EA200001105A1 (ru) 2001-04-23
AU3618699A (en) 1999-11-16
NO20005351L (no) 2000-10-24
GB9808894D0 (en) 1998-06-24
IL139018A0 (en) 2001-11-25
KR20010042929A (ko) 2001-05-25
JP2002513020A (ja) 2002-05-08
HUP0102298A2 (hu) 2002-05-29
SK15902000A3 (sk) 2001-05-10
AP2000001958A0 (en) 2000-12-31
CA2329913A1 (en) 1999-11-04
EP1076659A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20014047L (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
NO993051L (no) Intranasale formuleringer for behandling av seksuelle forstyrrelser
NO20012916L (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
DK1165510T3 (da) 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO20003211D0 (no) Triazinforbindelser for behandling av CNS forstyrrelser
NO20011892L (no) 3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
NO20026005D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20010390D0 (no) Behandling av angstsykdommer
NO991675D0 (no) FremgangsmÕte for alkylering av hindrede sulfonamider
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO20030127D0 (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20026029L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
ID26083A (id) Paroksetina 10-kamforsulfonat untuk pengobatan gangguan cns
NO20026028D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO993948D0 (no) Anvendelse av aryl-cykloheksylamin-derivater mot CNS-forstyrrelser
NO20006383L (no) Fremgangsmåte for behandling
NO20005351L (no) Paroksetin 10-kamfersulfonat for behandling av CNS lidelser
DK82798A (da) Treatment of GABA-uptake related disorders
NO996166D0 (no) Fremgangsmåte for behandling av avluter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application